These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 16869955

  • 1. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H.
    Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
    [Abstract] [Full Text] [Related]

  • 2. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H.
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [Abstract] [Full Text] [Related]

  • 3. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H.
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [Abstract] [Full Text] [Related]

  • 4. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
    Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.
    Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437
    [Abstract] [Full Text] [Related]

  • 5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Sep; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 6. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.
    Clin Cancer Res; 2006 Jan 01; 12(1):159-68. PubMed ID: 16397038
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 8. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS, Kim SW.
    Oncol Rep; 2007 Jul 12; 18(1):139-43. PubMed ID: 17549359
    [Abstract] [Full Text] [Related]

  • 9. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
    Cancer Invest; 2008 Aug 12; 26(7):671-9. PubMed ID: 18608215
    [Abstract] [Full Text] [Related]

  • 10. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Aug 12; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

  • 11. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA, de Bock GH, de Vries J, van der Vegt B, Wesseling J.
    J Surg Res; 2007 Jun 01; 140(1):109-14. PubMed ID: 17291532
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
    Kim HS, Yom CK, Kim HJ, Lee JW, Sohn JH, Kim JH, Park YL, Ahn SH.
    Breast Cancer Res Treat; 2010 Jun 01; 121(3):777-88. PubMed ID: 19806450
    [Abstract] [Full Text] [Related]

  • 13. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y.
    Eur J Cancer; 2006 Mar 01; 42(5):629-35. PubMed ID: 16464571
    [Abstract] [Full Text] [Related]

  • 14. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.
    Horiguchi J, Koibuchi Y, Iijima K, Yoshida T, Takata D, Rokutanda N, Nagaoka R, Oyama T, Iino Y, Morishita Y.
    Oncol Rep; 2005 Nov 01; 14(5):1109-16. PubMed ID: 16211272
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G, IMPACT Trialists Group.
    J Natl Cancer Inst; 2007 Jan 17; 99(2):167-70. PubMed ID: 17228000
    [Abstract] [Full Text] [Related]

  • 16. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD.
    Stem Cells; 2002 Jan 17; 20(1):32-40. PubMed ID: 11796920
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.
    Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW.
    Br J Cancer; 1999 Mar 17; 79(7-8):1220-6. PubMed ID: 10098763
    [Abstract] [Full Text] [Related]

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 17; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 19. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Jul 17; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 20. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.